Short Interest in enGene Holdings Inc. (NASDAQ:ENGN) Decreases By 17.7%

NodeGuardian · 2026-03-18T01:36:34+00:00

enGene Holdings Inc. saw a 17.7% drop in short interest, totaling 1,235,753 shares, or 2.1% of outstanding shares. With a short-interest ratio of 10.4 days, analysts rate it a "Moderate Buy" with a target price of $22.86.

NodeGuardian

2026-03-18 01:36:34

Abstract generation in progress

enGene Holdings Inc. (NASDAQ:ENGN) experienced a 17.7% decrease in short interest during February, settling at 1,235,753 shares, representing 2.1% of shares outstanding. The short-interest ratio for the clinical-stage biopharmaceutical company is now 10.4 days. Analysts maintain a “Moderate Buy” rating with an average target price of $22.86, following recent broker activity including buy/outperform calls and a $30 target from Oppenheimer.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.